A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination

被引:82
作者
Yu, Zeyuan [1 ]
Jiang, Xiangyan [1 ]
Qin, Long [2 ]
Deng, Haixiao [1 ]
Wang, Jianli [2 ]
Ren, Wen [2 ]
Li, Hongbin [2 ]
Zhao, Lei [2 ]
Liu, Huanxiang [3 ]
Yan, Hong [4 ]
Shi, Wengui [2 ]
Wang, Qi [5 ]
Luo, Changjiang [1 ]
Long, Bo [1 ]
Zhou, Huinian [1 ]
Sun, Hui [2 ]
Jiao, Zuoyi [1 ,2 ]
机构
[1] Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730000, Gansu, Peoples R China
[2] Lanzhou Univ, Hosp 2, Cuiying Expt Ctr, Lanzhou 730000, Gansu, Peoples R China
[3] Lanzhou Univ, Sch Pharm, Lanzhou 730000, Gansu, Peoples R China
[4] Lanzhou Univ, Hosp 2, Dept Pathol, Lanzhou 730000, Gansu, Peoples R China
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Ctr, Boston, MA 02215 USA
基金
中国国家自然科学基金;
关键词
CONJUGATING ENZYME UBE2T; E2; WNT; METHYLATION; PROMOTER; PATHWAY; FANCD2; BINDS; DNA;
D O I
10.1038/s41388-020-01572-w
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dysregulation of the Wnt/beta-catenin signaling pathway is critically involved in gastric cancer (GC) progression. However, current Wnt pathway inhibitors being studied in preclinical or clinical settings for other cancers such as colorectal and pancreatic cancers are either too cytotoxic or insufficiently efficacious for GC. Thus, we screened new potent targets from beta-catenin destruction complex associated with GC progression from clinical samples, and found that scaffolding protein RACK1 deficiency plays a significant role in GC progression, but not APC, AXIN, and GSK3 beta. Then, we identified its upstream regulator UBE2T which promotes GC progression via hyperactivating the Wnt/beta-catenin signaling pathway through the ubiquitination and degradation of RACK1 at the lysine K172, K225, and K257 residues independent of an E3 ligase. Indeed, UBE2T protein level is negatively associated with prognosis in GC patients, suggesting that UBE2T is a promising target for GC therapy. Furthermore, we identified a novel UBE2T inhibitor, M435-1279, and suggested that M435-1279 acts inhibit the Wnt/beta-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1, resulting in suppression of GC progression with lower cytotoxicity in the meantime. Overall, we found that increased UBE2T levels promote GC progression via the ubiquitination of RACK1 and identified a novel potent inhibitor providing a balance between growth inhibition and cytotoxicity as well, which offer a new opportunity for the specific GC patients with aberrant Wnt/beta-catenin signaling.
引用
收藏
页码:1027 / 1042
页数:16
相关论文
共 47 条
[1]   Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives [J].
Abdi, Esmat ;
Latifi-Navid, Saeid ;
Zahri, Saber ;
Yazdanbod, Abbas ;
Pourfarzi, Farhad .
CANCER MEDICINE, 2019, 8 (13) :6114-6126
[2]   Gastric Cancer, Version 3.2016 [J].
Ajani, Jaffer A. ;
D'Amico, Thomas A. ;
Almhanna, Khaldoun ;
Bentrem, David J. ;
Chao, Joseph ;
Das, Prajnan ;
Denlinger, Crystal S. ;
Fanta, Paul ;
Farjah, Farhood ;
Fuchs, Charles S. ;
Gerdes, Hans ;
Gibson, Michael ;
Glasgow, Robert E. ;
Hayman, James A. ;
Hochwald, Steven ;
Hofstetter, Wayne L. ;
Ilson, David H. ;
Jaroszewski, Dawn ;
Johung, Kimberly L. ;
Keswani, Rajesh N. ;
Kleinberg, Lawrence R. ;
Korn, W. Michael ;
Leong, Stephen ;
Linn, Catherine ;
Lockhart, A. Craig ;
Ly, Quan P. ;
Mulcahy, Mary F. ;
Orringer, Mark B. ;
Perry, Kyle A. ;
Poultsides, George A. ;
Scott, Walter J. ;
Strong, Vivian E. ;
Washington, Mary Kay ;
Weksler, Benny ;
Willett, Christopher G. ;
Wright, Cameron D. ;
Zelman, Debra ;
McMillian, Nicole ;
Sundar, Hema .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1286-1312
[3]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[4]   Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma [J].
Alagpulinsa, David A. ;
Kumar, Subodh ;
Talluri, Srikanth ;
Nanjappa, Purushothama ;
Buon, Leutz ;
Chakraborty, Chandraditya ;
Samur, Mehmet K. ;
Szalat, Raphael ;
Shammas, Masood A. ;
Munshi, Nikhil C. .
BLOOD ADVANCES, 2019, 3 (23) :3968-3972
[5]   UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: A basis for the regulation of FANCD2 monoubiquitination [J].
Alpi, Arno ;
Langevin, Frederic ;
Mosedale, Georgina ;
Machida, Yuichi J. ;
Dutta, Anindya ;
Patel, Ketan J. .
MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (24) :8421-8430
[6]   WNT signalling pathways as therapeutic targets in cancer [J].
Anastas, Jamie N. ;
Moon, Randall T. .
NATURE REVIEWS CANCER, 2013, 13 (01) :11-26
[7]  
Bang YJ, 2010, LANCET, V376, P1302
[8]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[9]   Comprehensive molecular characterization of human colon and rectal cancer [J].
Muzny, Donna M. ;
Bainbridge, Matthew N. ;
Chang, Kyle ;
Dinh, Huyen H. ;
Drummond, Jennifer A. ;
Fowler, Gerald ;
Kovar, Christie L. ;
Lewis, Lora R. ;
Morgan, Margaret B. ;
Newsham, Irene F. ;
Reid, Jeffrey G. ;
Santibanez, Jireh ;
Shinbrot, Eve ;
Trevino, Lisa R. ;
Wu, Yuan-Qing ;
Wang, Min ;
Gunaratne, Preethi ;
Donehower, Lawrence A. ;
Creighton, Chad J. ;
Wheeler, David A. ;
Gibbs, Richard A. ;
Lawrence, Michael S. ;
Voet, Douglas ;
Jing, Rui ;
Cibulskis, Kristian ;
Sivachenko, Andrey ;
Stojanov, Petar ;
McKenna, Aaron ;
Lander, Eric S. ;
Gabriel, Stacey ;
Getz, Gad ;
Ding, Li ;
Fulton, Robert S. ;
Koboldt, Daniel C. ;
Wylie, Todd ;
Walker, Jason ;
Dooling, David J. ;
Fulton, Lucinda ;
Delehaunty, Kim D. ;
Fronick, Catrina C. ;
Demeter, Ryan ;
Mardis, Elaine R. ;
Wilson, Richard K. ;
Chu, Andy ;
Chun, Hye-Jung E. ;
Mungall, Andrew J. ;
Pleasance, Erin ;
Robertson, A. Gordon ;
Stoll, Dominik ;
Balasundaram, Miruna .
NATURE, 2012, 487 (7407) :330-337
[10]   Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial [J].
Cats, Annemieke ;
Jansen, Edwin P. M. ;
van Grieken, Nicole C. T. ;
Sikorska, Karolina ;
Lind, Pehr ;
Nordsmark, Marianne ;
Kranenbarg, Elma Meershoek-Klein ;
Boot, Henk ;
Trip, Anouk K. ;
Swellengrebel, H. A. Maurits ;
van Laarhoven, Hanneke W. M. ;
Putter, Hein ;
van Sandick, Johanna W. ;
Henegouwen, Mark I. van Berge ;
Hartgrink, Henk H. ;
van Tinteren, Harm ;
van de Velde, Cornelis J. H. ;
Verheij, Marcel .
LANCET ONCOLOGY, 2018, 19 (05) :616-628